Home » ETF » IBBJ

IBBJ - Defiance Junior Biotech ETF

Stock Price: $32.23 USD 1.02 (3.27%)
Updated Apr 21, 2021 3:01 PM EDT - Market open
Assets $7.89M
NAV $31.58
Expense Ratio 0.45%
PE Ratio n/a
Beta (5Y) 2.13
Dividend (ttm) $0.30
Dividend Yield 0.95%
Ex-Dividend Date Dec 29, 2020
1-Year Return -
Trading Day April 21
Last Price $32.23
Previous Close $31.21
Change ($) 1.02
Change (%) 3.27%
Day's Open 31.40
Day's Range 31.40 - 32.23
Day's Volume 2,910
52-Week Range 22.85 - 41.45

Fund Description

The investment seeks to track the total return performance, before fees and expenses, of the NASDAQ Junior Biotechnology Index. The index is a rules-based index that consists of a portfolio of the stock of U.S.-listed small capitalization (junior) biotechnology companies (collectively, Junior Biotech Companies). The fund will generally use a replication strategy to achieve its investment objective, meaning it will generally invest in all of the component securities of the index in the same approximate proportions as in the index. The fund is non-diversified.

Asset Class
Inception Date
Aug 3, 2020
Ticker Symbol
Index Tracked
Nasdaq Junior Biotechnology Index

Top 10 Holdings

18.52% of assets
BridgeBio PharmaBBIO2.36%
Zai LabZLAB2.27%
Fate TherapeuticsFATE2.00%
GW PharmaceuticalsGWPH1.85%
Pacific Biosciences of CaliforniaPACB1.77%
Twist BioscienceTWST1.75%
Medpace HoldingsMEDP1.68%
Vir BiotechnologyVIR1.64%
Halozyme TherapeuticsHALO1.61%
View More Holdings


Ex-DividendAmountPay Date
Mar 24, 2021$0.00Mar 26, 2021
Dec 29, 2020$0.30Dec 31, 2020
Full Dividend History


Hide News
  • All
  • Videos
  • Conversation

Small cap stocks are retreating. So are biotechnology names.

3 weeks ago - ETF Trends

After a lull in mergers and acquisitions activity, Big Pharma could begin to use its cash stores to buy out smaller targets, potentially fueling the momentum in biotechnology-related exchange traded fun...

Other tickers mentioned: SBIO, XBI
3 months ago - ETF Trends

There are recipes for success for new exchange-traded funds. In an effort to attract assets and investors' attention, rookie ETFs can undercut established rivals on fees, offer exposure to a compelling ...

5 months ago - Benzinga

The Defiance Nasdaq Junior Biotechnology ETF (IBBJ) is just a few months in, but it's already asserting itself in the biotechnology exchange traded funds arena, one teeming with competition. IBBJ tracks...

5 months ago - ETF Trends

NEW YORK--(BUSINESS WIRE)---- $IBBJ #Biotech--About Defiance: Founded in 2018, Defiance ETFs is an exchange-traded funds (ETFs) sponsor and registered investment advisor, focused on thematic investing. ...

5 months ago - Business Wire

After a superb August, September looks gloomy for Wall Street. Still,

Other tickers mentioned: BBP, BETZ, PBD, RTM
6 months ago - Zacks Investment Research

The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.

Other tickers mentioned: BBC, BTEC, IDNA, MRNS, NVUS, PTH, SAVA ...
7 months ago - Zacks Investment Research

The S&P 500, the Dow Jones and the Nasdaq Composite have lost about 0.6%, 0.03% and 0.6%, respectively, past week.

Other tickers mentioned: BTEC, BETZ, LIT
7 months ago - Zacks Investment Research

Biotechnology mergers and acquisitions appear to be back in a big way with news that Gilead Sciences (NASDAQ: GILD) is acquiring Immunomedics (NASDAQ: IMMU) for $21 billion.

Other tickers mentioned: BTEC, PTH
7 months ago - Benzinga

The Defiance Nasdaq Junior Biotechnology ETF (IBBJ) is still in its infancy in the biotechnology ETFs arena, having debuted just last month, but a big opportunity comes with this rookie ETF. IBBJ tracks...

7 months ago - ETF Trends

The Defiance Nasdaq Junior Biotechnology ETF (NYSE: IBBJ) is the newest addition to the biotechnology exchange traded funds fray, having debuted about a month ago.

7 months ago - Benzinga

Small-cap biotech ETFs may prove to be winning bets with or without coronavirus.

Other tickers mentioned: BBC, BTEC, IDNA
7 months ago - Zacks Investment Research

ETF Trends CEO Tom Lydon discussed the Defiance Nasdaq Junior Biotechnology ETF (IBBJ) on this week’s “ETF of the Week” podcast with Chuck Jaffe on the MoneyLife Show. IBBJ covers companies around the g...

8 months ago - ETF Trends

The Defiance Nasdaq Junior Biotechnology ETF (IBBJ) is one of the newest exchange traded funds on the market and it could be one of the most appropriate for the current environment. IBBJ’s 176 member fi...

8 months ago - ETF Trends

Extending what’s been a busy stretch of unique healthcare ETF launches, the Defiance Nasdaq Junior Biotechnology ETF (IBBJ) debuted on Tuesday, coming to market at a time when biotechnology ETFs, broadl...

8 months ago - ETF Trends

With significant help from the fight against the coronavirus, biotechnology stock and exchange-traded funds are setting torrid paces this year.

8 months ago - Benzinga

New fund invests in small-cap biotechnology stocks. 

Other tickers mentioned: IBB, XBI
8 months ago - ETFcom

Defiance ETFs debuted a new ETF today with targeted exposure to the junior disruptors in the biotech space.

8 months ago - ETF Trends